Evidence map›Paper›PMID 38390966›Full record

ArticleProteomes2024

Observations from the Proteomics Bench.

Simone König, Karin Schork, Martin Eisenacher

Abstract read
In one paragraph

Article in Proteomes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Simone KönigIZKF Core Unit Proteomics, University of Münster, 48149 Münster, Germany.ORCID 0000-0003-0672-7246
Karin SchorkMedizinisches Proteom-Center, Medical Faculty, Ruhr-University Bochum, 44801 Bochum, Germany.ORCID 0000-0003-3756-4347
Martin EisenacherMedizinisches Proteom-Center, Medical Faculty, Ruhr-University Bochum, 44801 Bochum, Germany.ORCID 0000-0003-2687-7444

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many challenges in proteomics result from the high-throughput nature of the experiments. This paper first presents pre-analytical problems, which still occur, although the call for standardization in omics has been ongoing for many years. This article also discusses aspects that affect bioinformatic analysis based on three sets of reference data measured with different orbitrap instruments. Despite continuous advances in mass spectrometer technology as well as analysis software, data-set-wise quality control is still necessary, and decoy-based estimation, although challenged by modern instruments, should be utilized. We draw attention to the fact that numerous young researchers perceive proteomics as a mature, readily applicable technology. However, it is important to emphasize that the maximum potential of the technology can only be realized by an educated handling of its limitations.

Indexed as

bioinformaticsfalse positivesmass spectrometryproteomics

Identifiers

PMID38390966
PMCPMC10885119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.